Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cellebrite DI (CLBT) Gross Profit (2020 - 2025)

Historic Gross Profit for Cellebrite DI (CLBT) over the last 6 years, with Q3 2025 value amounting to $105.7 million.

  • Cellebrite DI's Gross Profit rose 1564.42% to $105.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $382.8 million, marking a year-over-year increase of 1768.19%. This contributed to the annual value of $338.6 million for FY2024, which is 2454.44% up from last year.
  • Per Cellebrite DI's latest filing, its Gross Profit stood at $105.7 million for Q3 2025, which was up 1564.42% from $95.6 million recorded in Q2 2025.
  • Cellebrite DI's 5-year Gross Profit high stood at $105.7 million for Q3 2025, and its period low was $45.1 million during Q1 2021.
  • In the last 5 years, Cellebrite DI's Gross Profit had a median value of $63.7 million in 2023 and averaged $69.8 million.
  • As far as peak fluctuations go, Cellebrite DI's Gross Profit surged by 76.37% in 2022, and later soared by 2973.07% in 2024.
  • Quarter analysis of 5 years shows Cellebrite DI's Gross Profit stood at $55.6 million in 2021, then grew by 11.36% to $61.9 million in 2022, then increased by 26.19% to $78.1 million in 2023, then increased by 17.07% to $91.4 million in 2024, then rose by 15.63% to $105.7 million in 2025.
  • Its last three reported values are $105.7 million in Q3 2025, $95.6 million for Q2 2025, and $90.1 million during Q1 2025.